Notification of Interim Results

RNS Number : 6598T

ReNeuron Group plc

18 November 2019

 

18 November 2019

AIM: RENE

ReNeuron Group plc

("ReNeuron" or the "Company")

Notification of Interim Results

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its interim results for the six months ended 30 September 2019 on Friday 6 December 2019.

A meeting for analysts will be held at 09.30am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

To access a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 09.30am on the day of the results:

https://webcasting.buchanan.uk.com/broadcast/5dcc32879535b1405a05b0bd 

A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.

                                                                        ENDS

Contacts: ReNeuron	[phone]
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK Media/Investor Relations)	[phone]
Mark Court, Tilly Abraham
Argot Partners (US Media/Investor Relations) Claudia Styslinger, David Rosen	[phone]
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Jonathan Senior, Stewart Wallace, Ben Maddison	[phone]
N+1 Singer (Joint Broker) Aubrey Powell, James Moat, Mia Gardner	[phone]

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

 

END

 

 

NOREANFXFDANFFF